PMID- 32189318
OWN - NLM
STAT- MEDLINE
DCOM- 20211126
LR  - 20211126
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 129
IP  - 6
DP  - 2021 Jun
TI  - HOMA-Adiponectin Closely Associates with Cardiometabolic Risk Markers in 
      Middle-Aged Indians with Metabolic Syndrome.
PG  - 449-456
LID - 10.1055/a-1120-8163 [doi]
AB  - BACKGROUND: Unhealthy dietary habits and sedentary lifestyles have raised 
      alarming concerns for the rising prevalence of metabolic syndrome (MetS) and 
      associated cardiometabolic risk among Indians at an early age. Insulin resistance 
      and adiposity are the important risk factors associated with MetS. The present 
      study aimed to investigate the relationship between a modified marker of insulin 
      resistance (homeostatic model assessment-adiponectin (HOMA-AD)) and 
      cardiometabolic risk among middle-aged Indians. METHODS: The study comprised of 
      144 subjects of age-group 31-50 years, where 83 subjects were diagnosed for MetS 
      according to the guidelines given by the International Diabetes Federation. We 
      measured cardiometabolic risk indicators such as fasting blood glucose (FPG), 
      fasting plasma insulin (FPI), homeostatic model assessment- insulin resistance 
      (HOMA-IR), adiponectin, high sensitivity C-reactive protein (hs-CRP), oxidized 
      LDL (oxLDL), monocyte chemoattractant protein-1 (MCP-1), and atherogenic index, 
      among others. We calculated HOMA-AD by the formula: [FPG (mmol/l) x FPI (microIU/ml)] 
      / [22.5 x Adiponectin (microg/ml)]. RESULTS: HOMA-IR and HOMA-AD were highly 
      increased (p<0.001) in the MetS subjects than controls. Adiponectin was 
      significantly (p<0.01) lower whereas cardiac risk markers such as atherogenic 
      index, hs-CRP, oxLDL, and MCP-1 were significantly (p<0.01) elevated in MetS 
      group than controls. Linear regression showed positive and significant 
      associations (p<0.01) of HOMA-AD with all the cardiometabolic risk markers except 
      MCP-1. HOMA-AD showed higher AUC (0.806) than HOMA-IR (0.791) for predicting 
      MetS. CONCLUSION: HOMA-AD could be a surrogate adipokine-based marker correlated 
      significantly with components of MetS and cardiometabolic risk indicators. It 
      appeared to be a better predictor of MetS among middle-aged Indians than HOMA-IR.
CI  - Thieme. All rights reserved.
FAU - Banerjee, Joyita
AU  - Banerjee J
AD  - Symbiosis School of Biological Sciences, Symbiosis International (Deemed 
      University), Lavale, Pune, India.
FAU - Dhas, Yogita
AU  - Dhas Y
AD  - Symbiosis School of Biological Sciences, Symbiosis International (Deemed 
      University), Lavale, Pune, India.
FAU - Mishra, Neetu
AU  - Mishra N
AD  - Symbiosis School of Biological Sciences, Symbiosis International (Deemed 
      University), Lavale, Pune, India.
LA  - eng
PT  - Journal Article
DEP - 20200318
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German 
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
RN  - 0 (ADIPOQ protein, human)
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adiponectin/*blood
MH  - Adult
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/*blood
MH  - Female
MH  - Homeostasis/physiology
MH  - Humans
MH  - India
MH  - Insulin Resistance/*physiology
MH  - Male
MH  - Metabolic Syndrome/*blood
MH  - Middle Aged
COIS- The authors declare that they do not have any conflicts.
EDAT- 2020/03/20 06:00
MHDA- 2021/11/27 06:00
CRDT- 2020/03/20 06:00
PHST- 2020/03/20 06:00 [pubmed]
PHST- 2021/11/27 06:00 [medline]
PHST- 2020/03/20 06:00 [entrez]
AID - 10.1055/a-1120-8163 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2021 Jun;129(6):449-456. doi: 10.1055/a-1120-8163. 
      Epub 2020 Mar 18.